Ovarian Epithelial, Fallopian Tube, and Primary Peritoneal Cancer Treatment (PDQ®)–Health Professional Version

OVARIAN, FALLOPIAN TUBE, AND PRIMARY PERITONEAL CANCER

SECTIONS

Changes to This Summary (07/28/2017)

Advanced-Stage Ovarian Epithelial Cancer, FTC, and PPC Treatment

Revised text to state that the positive results from the Japanese Gynecologic Oncology Group 3016 study have been widely adopted and also led to new divided-dose paclitaxel studies.

Added text about GOG-0262, a phase III study that compared weekly paclitaxel to every-3-week dosing, both with the conventional every-3-week carboplatin (AUC 6) regimen and an option to give bevacizumab every 3 weeks beginning with cycle two and continuing until cycle six (cited Chan et al. as reference 28 and level of evidence 1iiDiii). Also added text to state that overall, the weekly paclitaxel regimen failed to prolong progression-free survival (PFS) compared with the every-3-week regimen; however, among patients not receiving bevacizumab, the weekly paclitaxel arm had significantly prolonged PFS.

Expanded Table 7 to include GOG-0262 as an additional trial.

Recurrent or Persistent Ovarian Epithelial Cancer, FTC, and PPC Treatment

Revised Table 9 to include paclitaxel-carboplatin as an additional regimen (cited Coleman et al. as reference 10).

Revised text to state bevacizumab with gemcitabine-carboplatin chemotherapy as evidence for bevacizumab with chemotherapy.

Added additional evidence for bevacizumab with paclitaxel-carboplatin chemotherapy.

This summary is written and maintained by the PDQ Adult Treatment Editorial Board, which is editorially independent of NCI. The summary reflects an independent review of the literature and does not represent a policy statement of NCI or NIH. More information about summary policies and the role of the PDQ Editorial Boards in maintaining the PDQ summaries can be found on the About This PDQ Summary and PDQ® - NCI's Comprehensive Cancer Database pages.

< Previous section
Recurrent or Persistent Ovarian Epithelial Cancer, FTC, and PPC Treatment

Next section >
About This PDQ Summary